In a clinical pilot study involving patients undergoing neoadjuvant chemotherapy, we explored evidence that diffuse optical tomography can be used to monitor tumor progression and predict treatment response.
© 2018 The Author(s)
You do not have subscription access to this journal. Citation lists with outbound citation links are available to subscribers only. You may subscribe either as an OSA member, or as an authorized user of your institution.
Contact your librarian or system administrator
Login to access OSA Member Subscription